Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.56 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.56 |
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 7/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | THRA | P10827 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20568113 | 0.91 | CHRNB2 (0.54) | CHRNB2CHRNA4UTS2RCYP19A1KDM4E | |
| SCHEMBL1012155 | 0.83 | HTT (0.45) | CYP19A1ALDH1A1TSHRTDP1S1PR4 | |
| SCHEMBL5509909 | 0.82 | CHRNB2 (0.59) | CHRNB2CHRNA4CYP19A1KDM4EGAA | |
| SCHEMBL4548252 | 0.82 | CHRNB2 (0.59) | CHRNB2CHRNA4CYP19A1KDM4EGAA | |
| SCHEMBL29458124 | 0.81 | CHRNB2 (0.58) | CHRNB2CHRNA4UTS2RCYP19A1KDM4E | |
| SCHEMBL29458175 | 0.81 | CHRNB2 (0.58) | CHRNB2CHRNA4CYP19A1KDM4EGAA | |
| SCHEMBL1219905 | 0.81 | CHRNB2 (0.58) | CHRNB2CHRNA4CYP19A1KDM4EGAA | |
| SCHEMBL5275797 | 0.81 | CHRNB2 (0.58) | CHRNB2CHRNA4CYP19A1KDM4EGAA | |
| SCHEMBL7396303 | 0.81 | CHRNB2 (0.58) | CHRNB2CHRNA4UTS2RCYP19A1KDM4E | |
| SCHEMBL7399032 | 0.81 | CHRNB2 (0.58) | CHRNB2CHRNA4CYP19A1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531553-B2 | Heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-05-12 | — | — | US | disclosed |
| EP-1638954-A1 | FUSED AZOLES SUCH AS 2,5-DISUBSTITUTED BENZIMIDAZOLES, BENZOXAZOLES AND BENZOTHIAZOLES AS KINASE INHIBITORS | AMGEN INC. (US) | 2006-03-29 | — | — | EP | disclosed |
| EP-1385495-A4 | SULFONAMIDES | SMITHKLINE BEECHAM CORP (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20050043536-A1 | antagonists of urotensin II; for example, 2,6-Dichloro-N-[3-(dimethylamino-ethoxy)4-trifluoromethyl-phenyl]-4trifluoromethyl-benzenesulfonamide | SMITHKLINE BEECHAM CORPORATION | 2005-02-24 | — | — | US | disclosed |
| US-20040209892-A1 | Heterocyclic compounds and methods of use | U.S. PATENT OPERATIONS | 2004-10-21 | — | — | US | disclosed |
| WO-2004085425-A1 | FUSED AZOLES SUCH AS 2,5-DISUBSTITUTED BENZIMIDAZOLES, BENZOXAZOLES AND BENZOTHIAZOLES AS KINASE INHIBITORS | AMGEN INC (US) | 2004-10-07 | — | — | WO | disclosed |
| EP-1385495-A2 | SULFONAMIDES | SmithKline Beecham Corporation (US) | 2004-02-04 | — | — | EP | disclosed |
| WO-2002089740-A2 | SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043536-A1 | antagonists of urotensin II; for example, 2,6-Dichloro-N-[3-(dimethylamino-ethoxy)4-trifluoromethyl-phenyl]-4trifluoromethyl-benzenesulfonamide | UTS2R, SPINT2, PRSS2 | CHRNB2 1883/4885CHRNA4 3547/4885UTS2R 1/4885 |
| US-20040209892-A1 | Heterocyclic compounds and methods of use | VHL, NQO1, HPGDS | CHRNB2 4743/4885CHRNA4 4766/4885UTS2R 2684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.